Last Updated: 17 Sep 2024
Executive Summary
Koninklijke Philips NV ADR (PHG) is a healthcare technology company with a market capitalization of $28.65 billion. The company has been facing challenges in recent quarters, with negative EPS and a low profit margin. However, analysts remain optimistic about the company's long-term prospects, with a consensus analyst target price of $27.4.
Company Overview
Philips is a global leader in healthcare technology, with operations in North America, Greater China, and internationally. The company's products and services include medical imaging, patient monitoring, and healthcare informatics. Philips has a long history of innovation, dating back to its founding in 1891.
Fundamental Analysis
Philips' financial performance has been mixed in recent quarters. The company reported a loss per share of $0.65 in the latest quarter, and its profit margin was -0.0232. However, the company's revenue grew by 5.85% year-over-year, and its operating margin was 0.0623.
Philips' balance sheet is strong, with $12.72 in book value per share and $13.75 billion in EBITDA. The company's debt-to-equity ratio is 0.45, which is within a reasonable range.
Technical Analysis
Philips' stock price has been trending higher in recent months. The stock is currently trading above its 50-day and 200-day moving averages. The relative strength index (RSI) is 65, which indicates that the stock is overbought.
Short Term Outlook
In the short term, Philips' stock price could continue to trend higher. The company's financial performance is improving, and the stock is trading above its moving averages. However, the stock is overbought, so there is some risk of a pullback.
Long Term Outlook
In the long term, Philips' stock price is expected to rise. The company is a leader in the healthcare technology industry, and it has a strong balance sheet. The company's new products and services are expected to drive growth in the coming years.
Analyst Recommendations
Analysts are bullish on Philips' stock. The consensus analyst target price is $27.4, which represents a potential upside of 11.7% from the current price. One analyst has a strong buy rating on the stock, one has a hold rating, and one has a strong sell rating.
